Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vanguard Growth Index Fund ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Vanguard Growth Index Fund ETF trades at $89.15 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 395.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| MRVI | VUG | |
|---|---|---|
Market Cap | $972.90M | $384.60B |
Volume | 4,325,710 | 4,518,036 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $92.64 |
52-Week Low | $2.83 | $70.00 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VUG trades at $91.75, up 0.12% with a bullish technical outlook supported by moving averages. The ETF maintains strong historical performance with 12% average annual returns since 2004, concentrated in mega-cap technology stocks like Nvidia, Apple, and Microsoft. Recent dividend activity shows a $0.09 distribution scheduled for September 2026.
Long-term growth prospects remain favorable given VUG's track record and low expense ratio, though concentration risk in technology holdings and recent underperformance versus value funds present headwinds. The ETF suits investors with multi-decade horizons seeking large-cap growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
